Activity Stream
@moatrx
• 3 weeks ago
Posted a new blog:
US COLD AGGLUTININ DISEASE Competitive Intelligence
US COLD AGGLUTININ DISEASE Competitive Intelligence
Sutimlimab is the only approved CAD therapy, yet 54% of patients met the composite hemoglobin-response endpoint against off-label rituximab.
Cold agglutinin...



